NGC Update Service: September 28, 2015

National Guideline Clearinghouse (NGC)

September 28, 2015

New This Week

Guideline Summaries

American Pain Society

National Collaborating Centre for Cancer

National Collaborating Centre for Women's and Children's Health

Program in Evidence-based Care

Wound, Ostomy and Continence Nurses Society


Announcements

Conference News

  • The Guidelines International Network (G-I-N) 12th annual conference will take place from October 7–10, 2015 in Amsterdam. The theme is "Engaging all stakeholders. Guidelines from a societal perspective." To register and book a pre-conference course, visit the G-I-N Conference Web site.
  • Registration is now open for the Agency for Healthcare Research and Quality (AHRQ) 2015 Research Conference. It will be held October 4–6 at the Crystal Gateway Marriott Hotel and Convention Center in Crystal City, VA. The conference is titled "Producing Evidence and Engaging Partners to Improve Health Care." The latest version of the agenda is now available, including an updated list of speakers. Explore sessions and begin to plan your participation in the meeting. Visit the conference home page for more information.
  • The Guidelines International Network North America (G-I-N NA) continues to sponsor a monthly webinar series on topics of interest to the North American guideline community. Information on upcoming webinars, as well as audio files and slides from past webinars, is available on the G-I-N Web site.

U.S. Food and Drug Administration (FDA) Advisories

  • September 15, 2015: Clozapine: Drug Safety Communication - FDA Modifies Monitoring for Neutropenia; Approves New Shared REMS Program: FDA is making changes to the requirements for monitoring, prescribing, dispensing, and receiving the schizophrenia medicine clozapine, to address continuing safety concerns and current knowledge about a serious blood condition called severe neutropenia. Severe neutropenia is a dangerously low number of neutrophils, white blood cells that help fight infections. Severe neutropenia can be life-threatening.
  • September 21, 2015: Tramadol: Drug Safety Communication - FDA Evaluating Risks of Using in Children Aged 17 and Younger: FDA is investigating the use of the pain medicine tramadol in children aged 17 years and younger, because of the rare but serious risk of slowed or difficult breathing. This risk may be increased in children treated with tramadol for pain after surgery to remove their tonsils and/or adenoids. FDA is evaluating all available information and will communicate final conclusions and recommendations to the public when the review is complete.

Health Awareness Topics - September 2015

How to Participate

  • Submit Guidelines: Visit our Submit Guidelines page for information on how to submit your organization's guidelines.
  • Suggest a Guideline for Possible Inclusion: Submit your suggestions for evidence-based clinical practice guidelines that you would like to see included in NGC.
  • Suggest a Guideline Synthesis Topic: We welcome your suggestions for guideline synthesis topics!

NGC's Sister Resource

Look for Quality Measures in AHRQ's National Quality Measures Clearinghouse (NQMC).